Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.47 |
| ▸ | TYK2 | P29597 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1392970 | 0.82 | JAK2 (0.40) | BTKTYK2JAK2JAK1JAK3 | |
| SCHEMBL29741886 | 0.82 | BTK (0.49) | BTKCDK4CHRNB4CHRNA3 | |
| SCHEMBL14913085 | 0.82 | BTK (0.49) | BTKCDK4CHRNB4CHRNA3 | |
| SCHEMBL1393228 | 0.81 | BPTF (0.51) | CDK4 | |
| SCHEMBL24374822 | 0.78 | BTK (0.40) | BTKTYK2 | |
| SCHEMBL1393637 | 0.78 | BTK (0.49) | BTK | |
| SCHEMBL10257041 | 0.75 | CDK2 (0.45) | — | |
| SCHEMBL24374921 | 0.75 | BTK (0.40) | BTKTYK2JAK2JAK1 | |
| SCHEMBL24374692 | 0.73 | BTK (0.48) | BTK | |
| SCHEMBL24375305 | 0.72 | BTK (0.52) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A4, CYP4B1, CYP3A5 | BTK 3481/4885TYK2 1339/4885JAK2 977/4885 |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | BTK, SYK, LCK | BTK 1/4885TYK2 13/4885JAK2 12/4885 |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | BTK 2002/4885TYK2 1769/4885JAK2 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.